----

----

----

| (1) | CIMYM,      Inc. (company      registration number 12142) (“CIMYM”), a company incorporated in Barbados,      whose principal place of business is at Sagicor Centre, Wildey, St.      Michael, Barbados, West Indies;and |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2) | CIMAB      S.A. (company      registration number 107/92) (“CIMAB”), a company incorporated in Cuba,      whose principal place of business is at 206 Street, No. 1926, e/ 19 y 21,      Atabey, Playa, Havana City, Cuba;and |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (3) | Oncoscience      AG (company      registration number HRB 5414) (“Oncoscience”) a company incorporated in      Germany, whose principal place of business is at Hafenstraße 32, 22880      Wedel, Germany. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| A. | The Parties entered into a      development and licence agreement dated 17 November 2003 (the “Original      Agreement”). |
|----|---------------------------------------------------------------------------------------------------------------------------------------|

| B. | The Parties wish to enter into      this Agreement for the purposes of wholly replacing and superseding the      Original Agreement. |
|----|--------------------------------------------------------------------------------------------------------------------------------------|

| C. | CIMYM is the exclusive licensee      of certain Licensed Patent Rights, certain Licensed Know-how (each as      defined below) relating to an antibody known as TheraCIM h-R3 (as defined      below). |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| D. | The shareholders of CIMYM are YM      Biosciences, Inc. and CIMAB. |
|----|--------------------------------------------------------------------|

| E. | CIMAB enters into commercial      agreements on behalf of the Center of Molecular Immunology (“CIM”, as      defined below). CIM originally developed TheraCIM h-R3 and has the      facilities to manufacture Licensed Products (as defined below). CIMAB is      entering into this Agreement principally in order to assume the      manufacturing and supply obligations set out in Clause      5. |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| F. | Oncoscience has expertise in      cancer immunotherapy and experience in conducting immunotherapy clinical      trials in cancer patients. |
|----|--------------------------------------------------------------------------------------------------------------------------------------------|

| G. | Oncoscience wishes to pursue the      further development and commercialisation of TheraCIM h-R3 for the      treatment of cancer in humans, in accordance with the provisions of this      Agreement. |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| H. | CIMYM is willing to grant to      Oncoscience, and Oncoscience is willing to accept, a licence in the Field      under the Licensed Patent Rights and to use the Licensed Know-how, all in      accordance with the provisions of this  Agreement. |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| Affiliate | In relation to CIMYM or      Oncoscience, means any entity or person that controls, is controlled by,      or is under common control with that Party. For the purposes of this      definition, “control” shall mean direct or indirect beneficial ownership      of 50% (or, outside a Party’s home territory, such lesser percentage as is      the maximum, permitted level of foreign investment) or more of the share      capital, stock or other participating interest carrying the right to vote      or to distribution of profits of that entity or person, as the case may      be. |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Arising      Intellectual Property | Any and all of the Arising      Patents and the ArisingKnow-how. |
|------------------------------------|------------------------------------------------------------------|

| Arising      Know-how | Technical,      commercial and all other information generated by Oncoscienee or its      Affiliates or sub-licensees during the continuation of this Agreement that      relates to any of the Licensed Intellectual Property or the Licensed      Product, including any scientific or regulatory data (including clinical      data), product licence applications and approvals, clinical trial licence      applications and approvals, and development and marketing plans and      activities. |
|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Arising      Patents | Any      and all patents and patent applications that may be applied for or      obtained in respect of any invention(s) made by Oncoscience, its      Affiliates or sub-licensees during the continuation of this Agreement and      which relate to any Licensed Intellectual Property or the Licensed      Product, together with any continuations, continuations in part,      extensions, re-issues, divisions, and any patents, supplementary      protection certificates and similar rights that are based on or derive      priority from the foregoing. |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Calendar      Quarter | Each      three-month period ending on 31st      March, 30th      June, 30th      September and 3lst      December. |
|-----------------------|---------------------------------------------------------------------------------------------------------------------|

| Calendar      Year | A      year commencing on lst      January and ending on 31st      December (but commencing on the Commencement Date in the first year of      this Agreement and, in the final year of this Agreement, ending on the      date of the last sale of Licensed Product under this      Agreement). |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| CIM | The      Center of Molecular Immunology, a scientific research institute based in      Havana, Cuba. |
|-----|------------------------------------------------------------------------------------------------------|

| CIMAB’s      Contract Manufacturer | Any Person that may from time to      time be contracted by CIMAB to manufacture the Licensed Product, or any      component or ingredient thereof, in accordance with the provisions of this      Agreement. |
|------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| CIMYM Field      and Territory | (a) outside the Territory, all      fields (including the Field); and(b)      within the Territory, all fields other than the    Field). |
|--------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|

----

| Claims | All demands, claims and liability      (whether criminal or civil, in contract, tort or otherwise) for losses,      damages, legal costs and other expenses of any nature whatsoever and all      costs and expenses (including without limitation legal costs) incurred in      connection therewith. |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Co-exclusive      Licence | A licence      whereby: |
|---------------------------|-------------------------|

|  | (a) | both CIMAB and Oncoscienee may      exercise the licensed rights in the field and territory of the licence in      question |
|--|-----|-----------------------------------------------------------------------------------------------------------------------------|

|  | (b) | Oncoscience may grant      sub-licences to the extent permitted under Clause 6.4;      and |
|--|-----|--------------------------------------------------------------------------------------------|

|  | (c) | CIMAB may appoint a single,      further licensee from time to time in each part of such field and      territory to exercise such rights in its place,  but |
|--|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (d) | except as described in (c) above      CIMAB may not grant further licences in such field and territory for as      long as the co-exclusive licence continues, subject to the provisions of      this Agreement and the requirements of any applicable      law. |
|--|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Commencement      Date | The date of execution of this      Agreement by the Parties (or, if they sign on different dates, the last      date of signature of this Agreement by a  Party). |
|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Delivered      Items | Has the meaning given in Clause      4.2. |
|----------------------|-------------------------------------------|

| Development      and Commercialisation Plan | The development and      commercialisation plan for Licensed Product to be defined and agreed in      accordance with Clause 3.1, as amended from time to time by agreement in      writing of the Parties. An initial programme of work, which is anticipated      to form the basis of a more detailed Development and Commercialisation      Plan, is briefly summarised in the attached Schedule    3. |
|---------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Development      and Commercialisation Report | The report described in Clause      3.4 as amended from time totime. |
|-----------------------------------------------|----------------------------------------------------------------------|

| Development      Team Parties | CIMYM and Oncoscience, and      “Development Team Party” shall mean either of  them. |
|-------------------------------|--------------------------------------------------------------------------------------------------|

| Development      Term | In respect of each country in the      Territory, means the period from the Commencement Date until completion of      the development of TheraCIM h-R3 to the point of first commercial sale of      a Licensed Product in that country in accordance with the Development and      Commercialisation Plan. |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Diligent and      Reasonable Efforts | Exerting such efforts and      employing such resources (whether by itself or through sub-contractors or      sub-licensees) as would normally be exerted or employed by a reasonable      third party pharmaceutical company for a product of similar market      potential at a similar stage of its product life, when utilizing sound and      reasonable scientific, business and medical practice and judgment in order      to develop the product in a timely manner and maximize the economic return      to the Parties from its  commercialisation. |
|--------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| Field | The treatment of cancer in      humans. |
|-------|-----------------------------------------|

| Gross Sales      Value | Any and all amounts received      (including the value of any non-monetary consideration received) for the      sale of the Licensed Product by Oncoscience or its Affiliates from a third      party (including any of Oncoscience’s sub-licensees) in an arm’s length      transaction exclusively for money (or where the sale is not at arm’s      length, the price that would have been so invoiced and received if it had      been at arm’s length), after deduction of all      documented: |
|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (a) | normal trade discounts actually      granted and any credits actually given (including for rejected or returned      Licensed Product), |
|--|-----|-----------------------------------------------------------------------------------------------------------------------------------------|

|  | (b) | rebates to customers and third      parties, |
|--|-----|----------------------------------------------|

|  | (c) | provided the amounts are      separately charged on the relevant invoice any costs of packaging,      insurance, carriage andfreight, |
|--|-----|---------------------------------------------------------------------------------------------------------------------------------------|

|  | (d) | any value added tax or other      sales or use tax charged to thecustomer |
|--|-----|---------------------------------------------------------------------------|

|  | (e) | any import or export duties or      similar applicable government levies; provided that such deductions do not      exceed reasonable and customary amounts in the markets in which such sales      occurred; |
|--|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | provided      that in no event the total of deductions referred to in paragraphs (a) to      (e) above will exceed 10% (ten percent) of the total    invoice. |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Initial      Development Programme | A programme of development to be      conducted by Oncoscience in accordance with the provisions of Schedule 3      Part A. |
|------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|

| Joint      Development Team | A committee to be established,      and operating, in accordance with the provisions of Clause      2. |
|-----------------------------|--------------------------------------------------------------------------------------------------------|

| Know-how | The Licensed Know-how and the      Arising Know-how. |
|----------|------------------------------------------------------|

| Licensed      Intellectual Property | Any and all of the Licensed      Patent Rights and LicensedKnow-how. |
|-------------------------------------|----------------------------------------------------------------------|

| Licensed      Know-how | Technical information in the      possession of CIMYM or CIMAB in the Field relating to (a) TheraCIM h-R3      and/or (b) the inventions claimed in the Licensed Patent Rights, and being      further described in the attached Schedule 2, in each case to the extent      that such information is relevant to the development and commercialisation      of the Licensed Product. |
|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| Licensed      Patent Rights | The patents and patent      applications described in the attached Schedule 1 subject to the      provisions of Schedule 1, together with any continuations, continuations      in part, extensions, reissues, divisions, and any patents, supplementary      protection certificates and similar rights that are based on or derive      priority from the foregoing. |
|-----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Licensed      Product | TheraCIM h-R3 that is sold or      otherwise supplied by Oncoscience or its Affiliate or sub-licensee and      which (a) is within any Valid Claim of the Licensed Patent Rights and/or      (b) is the subject of any Orphan Drug Status in the Territory; and/or (c)      incorporates, or its development makes use of, any of the Licensed      Know-how. |
|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Major      Country | Germany, France, Italy, Spain or      the United Kingdom. |
|--------------------|-----------------------------------------------------------|

| Milestone      Receipts | The amount of any payment,      excluding Value Added Tax, (other than sales income on which Oncoscience      pays CIMYM a royalty under Clause 7.1 or 7.2, including any payments to      Oncoscience or its Affiliate for Licensed Product supplied directly by      Oncoscience or its Affiliate for sale or promotion by Oncoscience’s      Affiliates or sub-licensees) obtained by, or due to, Oncoscience or its      Affiliate and the value of any non-monetary receipt, in relation to the      development or sub-licensing (including the grant of any option over a      sub-licence) of any Licensed Intellectual Property (“Relevant      Transaction”), and including any of the following in relation to a      Relevant Transaction: |
|-------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (a) | up-front, licence, milestone      (whether at the stage of development, marketing or otherwise), success,      bonus, maintenance and periodic (including annual) fees and other      payments, and minimum royalty payments (to the extent not offset against      royalties based on sales and coming within the definition of Royalty      Receipts), due under any sub-licence  agreement; |
|--|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (b) | any receipt greater than actual      incurred cost in respect of the funding of research or development      activities related to the Licensed Product, provided that such incurred      costs shall not include any costs that were incurred prior to the date of      the agreement under which such funding was  provided; |
|--|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (c) | where any sub-licence is to be      granted under cross-licensing arrangements, the value of any third party      licence obtained under sucharrangements; |
|--|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (d) | any premium paid over the fair      market value of shares, options or other securities in respect of any of      the share capital of Oncoscience or its Affiliate (such fair market value      to be determined on the assumption that CIMYM had not granted, nor agreed      to grant, any rights to Oncoscience in respect of any Licensed      Intellectual Property); |
|--|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (e) | any loan, guarantee or other      financial benefit made or given other than on normal market terms;      and |
|--|-----|---------------------------------------------------------------------------------------------------------------|

----

|  | (f) | any shares, options or other      securities obtained from a thirdparty. |
|--|-----|--------------------------------------------------------------------------|

| Net Sales      Value | The Gross Sales Value after      deduction of the SupplyPrice. |
|----------------------|----------------------------------------------------------------|

| Oncoscience      Field and Territory | In respect of any activity that      is licensed to Oncoscience under this Agreement, shall mean that the      activity must occur both within the Field and within the      Territory. |
|--------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Orphan Drug      Status | The grant of “orphan designation”      by the European Commission for a medicinal product pursuant to Regulation      (EC) No. 141/2000 of 16 December 1999 or any similar designation in any      part of the Territory. |
|-------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Parties | CIMYM, CIMAB and Oncoscience, and      “Party” shall mean any ofthem. |
|---------|-----------------------------------------------------------------------------------|

| Person | Includes any individual, firm,      company, corporation or other legal  entity. |
|--------|----------------------------------------------------------------------------------|

| Patents | Any and all of the Licensed      Patent Rights and the ArisingPatents. |
|---------|------------------------------------------------------------------------|

| Payment      Cap | Has the meaning given in Clause      7.1. |
|------------------|-------------------------------------------|

| Providing      Parties | Any and all of CIMAB (whether on      its own behalf or on behalf of CIM) and CIMYM and Providing Party shall      mean either of them. |
|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|

| Regulatory      Application | Any and all applications that are      necessary and appropriate to obtain Regulatory Approval including, without      limitation, all required documents, data and information concerning, filed      or required to be filed, otherwise submitted by Oncoscience, its Affiliate      or licensee to a RegulatoryAuthority. |
|-----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Regulatory      Approval | Any and all approvals, licences,      registrations or authorisations of any Regulatory Authority that are      necessary for the manufacture, use, storage, import, export, transport,      marketing, distribution or sale of the Licensed Product in any part of the      Territory. |
|--------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Regulatory      Authority | The European Medicines Evaluation      Agency and other regulatory authorities in the      Territory. |
|---------------------------|-------------------------------------------------------------------------------------------------------|

| Supply      Agreement | Any agreement between CIMAB and      Oncoscience under which CIMAB agrees to manufacture and supply Oncoscience      with Licensed Product. |
|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------|

| Supply      Price | The commercial supply price for      the Licensed Product payable by Oncoscience to CIMAB in accordance with      Clause 5.2. |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------|

----

| Territory | Shall mean the following      countries and territories: Austria, Belgium, Denmark, Finland, France,      Germany, Greece, Ireland, Italy, Luxembourg, Portugal, Spain, Sweden, The      Netherlands, United Kingdom, Cyprus, Czech Republic, Estonia, Hungary,      Latvia, Lithuania, Malta, Poland, Slovakia, Slovenia, Bulgaria, Romania,      Turkey, Albania, Andorra, Belarus, Bosnia-Herzegovina, Croatia, Former      Yugoslav Republic of Macedonia, Iceland, Liechtenstein, Moldova, Monaco,      Norway, Russia, San Marino, Serbia and Montenegro, Switzerland, Ukraine      and Vatican City. |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| TheraCIM      h-R3 | A humanised antibody to the EGF      receptor, known scientifically as h-R3 and which has been given the      product name TheraCIM h-R3. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------|

| Third Party      Manufacturer | Has the meaning given in Clause      5.4. |
|-------------------------------|-------------------------------------------|

| Valid      Claim | A claim of a patent or patent      application that has not expired or been held invalid or unenforceable by      a court of competent jurisdiction in a final and non-appealable      judgment. |
|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2. | Joint Development      Team |
|----|-----------------------------|

| 2.1 | Formation. Within fifteen (15) days after      the Commencement Date, the Development Team Parties shall establish a      Joint Development Team, by each Development Team Party designating its      initial members to serve on the Joint Development Team and notifying the      other Development Team Party of its dates of availability for the first      meeting of the Joint Development Team. The purpose of the Joint      Development Team shall be to oversee the development of Licensed Product      for purposes of commercialisation in the Oncoscience Field and Territory.      The Joint Development Team shall consist of not more than three (3)      representatives designated by each Development Team Party. Each      representative shall have relevant and appropriate expertise in order to      oversee the development of the Licensed Product. If a representative of a      Development Team Party is unable to attend a meeting of the Joint      Development Team, such Development Team Party may designate an alternate      to attend such meeting. In addition, each Development Team Party may, at      its discretion, invite a reasonable number of other employees, consultants      or scientific advisors to attend the meetings of the Joint Development      Team, provided that such invitees are bound by appropriate confidentiality      obligations. Each Development Team Party may change one or all of its      representatives to the Joint Development Team at any time upon notice to      the other Development TeamParty. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.2 | Meetings. The Joint Development Team      shall meet quarterly and at such other times as the Parties may agree. The      first meeting of the Joint Development Team shall be held as soon as      reasonably practicable, but in no event later than 30 days after the      Commencement Date. Meetings shall be held at such place or places as are      mutually agreed or by teleconference or videoconference; provided,      however, that there shall be at least one face-to-face meeting per      calendar year. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 2.3 | Responsibilities. During the Development Term,      the Joint Development Teamshall: |
|-----|--------------------------------------------------------------------------------------|

|   | (a) | elaborate the Development      Commercialisation Plan in accordance with Clause  3.1 |
|--------|-----|--------------------------------------------------------------------------------------|

|   | (b) | review and unanimously approve      (or, if the members of the Joint Development Team are unable to reach      unanimous agreement, recommend to the Parties) the overall development      strategy for Licensed Product in the Oncoscience Field and Territory      (including, without limitation, setting criteria for progression of      Licensed Product to the next stage of development under the Development      and Commercialisation Plan); |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | review and recommend to the      Parties modifications to the Development and Commercialisation Plan      (including the resources to be allocated and the timelines contained in      the Development and Commercialisation  Plan); |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (d) | facilitate the transfer of      Know-How between the Parties for purposes of conducting the Development      and Commercialisation Plan; |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------|

|   | (e) | regularly assess the progress of      Oncoscience in its conduct of the Development and Commercialisation Plan;      and |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------|

|   | (f) | perform such other activities as      are contemplated under this Clause 2 and Clause 1. For the avoidance of      doubt the Joint Development Team shall not have any role or responsibility      in relation to determining whether Oncoscience has complied or will comply      with its obligations to CIMYM under Clauses 3 or  8. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.4 | Disputes. If agreement cannot be reached      within the Joint Development Team, Oncoscience shall have the right to      make the final determination concerning the resolution of the      disagreement. Notwithstanding the foregoing, in the case of a disagreement      involving a material matter, prior to invoking its rights under this      Clause 2.4, Oncoscience agrees to have its chief executive contact the      chief executive of CIMYM for the purpose of discussing the disagreement      and attempting to reach a consensus. It shall be the goal of the chief      executives to reach a consensus within five (5) days of the date on which      contact is initiated by the chief executive of Oncoscience, it being      understood that (i) in the event of an extraordinary circumstance      requiring a faster resolution (e.g., a safety issue or extraneous timing      issue), Oncoscience shall have the right to make the final determination      prior to the end of such five (5) day period if a consensus has not been      achieved by the required time for resolution and (ii) in the event that a      consensus has not been achieved within ten (10) days of the date on which      contact is initiated by the executive officer of Oncoscience, Oncoscience      shall have the right to make the final determination. For the avoidance of      doubt, Oncoscience shall not have any right, under this clause, to      determine whether it has complied or will comply with its obligations to      CIMYM under Clauses 2.4 or8. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3. | Development and      Commercialisation |
|----|----------------------------------------|

| 3.1 | Development      and Commercialisation Plan. |
|-----|----------------------------------------------|

| 3.1.1 | Within 90 days of the      Commencement Date, the Joint Development Team shall prepare a written plan      (“Development and Commercialisation Plan”) that expands upon the initial      development plan set out in Schedule 3 and will describe, and provide a      timeline for: |
|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | (a) | all development activities for      the Licensed Product in the Oncoscience Field and Territory, addressing      each phase of development and the budget for completion of such      activities, and providing detailed information on the activities to be      conducted in the next 12 monthperiod; |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | intellectual property protection      strategy, including applying for Orphan Drug Status, patents and      supplementary protectioncertificates |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | sub-licensing      strategy; |
|--------|-----|------------------------------|

|   | (d) | clinical and registration      strategy, with a view to expediting regulatory approval for Licensed      Product; and |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------|

|   | (e) | commercialisation      strategy. |
|--------|-----|----------------------------------|

| 3.1.2 | The Joint Development Team shall      update the Development and Commercialisation Plan on a regular basis (and      at least annually). |
|-------|------------------------------------------------------------------------------------------------------------------------------------------|

| 3.2 | Development      and commercialisation activities. Oncoscience shall be      responsible for the development and commercialisation (in accordance with      the Development and Commercialisation Plan) of the Licensed Product in the      Oncoscience Field and Territory. Such development and commercialisation      shall be carried out under the oversight and management of the Joint      Development Team and in accordance with the provisions of this      Agreement. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.3 | Development      and commercialisation costs. Oncoscience shall bear all      costs associated with the development and commercialisation of Licensed      Product in the Oncoscience Field and Territory, including costs incurred      in the Development and Commercialisation Plan. If any Providing Party      agrees with Oncoscience to conduct work as part of the Development and      Commercialisation Plan (which may include advice given to the Joint      Development Team), the Providing Party’s costs of conducting such work      shall be borne by Oncoscience, with the time costs of the Providing      Party’s representatives being charged to Oncoscience on a daily rate      basis. The Providing Party’s daily rate for its representatives in the      work referred to in the previous sentence shall be agreed between the      Parties or, if they are unable to agree, the rate shall be US$ 1,000 (one      thousand US dollars) per day plus any product-related consumable costs and      external costs associated with suchwork. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.4 | Reporting. Without prejudice to the      generality of Oncoscience’s obligations under Clauses 8.1 and 9.2,      Oncoscience shall provide a report (“Development and Commercialisation      Report”) to CIMYM at least annually to CIMYM. In addition, Oncoscience      shall provide to CIMYM a quarterly, written status update on all clinical,      development and commercial activities being undertaken, and from time to      time upon request, showing all past, current and projected activities      taken or to be taken by Oncoscience to bring Licensed Product to market      and maximise the sale of Licensed Product in the Oncoscience Field and      Territory, and including details of all Arising Intellectual Property.      CIMYM’s receipt or approval of any such report shall not be taken to waive      or qualify Oncoscience’s obligations under Clause    8.1. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.5 | Exchange of      data. It is CIMYM’s      or CIMAB’s intention to grant licences to commercialise TheraCIM h-R3 in      the CIMYM Field and Territory. Accordingly, each of the Parties or its      licensee(s), may generate data in relation to Licensed Products that is      useful to the other Parties in connection with their commercialisation of      Licensed Products. To facilitate such commercialisation, Oncoscience shall      disclose and provide to CIMYM and CIMAB all Arising Intellectual Property      in accordance with the provisions of Clause 3.4. CIMYM (or CIMAB as      applicable) and Oncoscience shall use reasonable efforts to reach      agreement with CIMYM’s (or CIMAB’s as applicable) other licensee(s) of      TheraCIM h-R3 for the disclosure to Oncoscience of clinical data in      respect of TheraCIM h-R3 that is generated by such      licensee(s). |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 4. | Know-how and Confidential      Information |
|----|--------------------------------------------|

| 4.1 | Provision of      Know-how. Upon      Oncoscience’s reasonable request, CIMYM shall supply Oncoscience with all      Licensed Know-how in its possession that is specifically relevant to the      development and commercialisation of TheraCIM h-R3 and that CIMYM is at      liberty to disclose and has not previously been disclosed and which is      reasonable necessary to enable Oncoscience to undertake the further      development of Licensed Product. The Licensed Know-how shall be subject to      the confidentiality provisions of Clause 4.4. The method of any such      supply shall be as specified in Schedule 2 but shall not require CIMYM to      undertake more than 5 man-days of work, unless otherwise agreed in writing      between the Parties. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.2 | Status of      Know-how.      Oncoscience acknowledges that the Licensed Know-how is subject to further      development. Accordingly, specific results cannot be guaranteed and any      results, materials, information or other items, including the Licensed      Know-how and inventions claimed in the Licensed Patent Rights (together      “Delivered Items”) provided under this Agreement are provided “as is” and      without any express or implied warranties, representations or      undertakings. As examples, but without limiting the foregoing, CIMYM does      not give any warranty that Delivered Items are of merchantable or      satisfactory quality, are fit for any particular purpose, comply with any      sample or description, or are viable, uncontaminated, safe or      non-toxic. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.3 | Use of      Know-how.      Oncoscience undertakes that for a period of 10 years from the date of      first commercial sale of Licensed Product in the Territory or for so long      as any substantial part of the Know-how remains subject to the obligations      of confidence of Clause 4.4, whichever is the shorter, it will not use the      Licensed Know-how for any purpose except as expressly licensed hereby and      in accordance with the provisions of this  Agreement. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.4 | Confidentiality      obligations. Each      Party (“Receiving Party”)undertakes: |
|-----|----------------------------------------------------------------------------------------------|

|   | (a) | to maintain as secret and      confidential all Know-how and other technical or commercial information      obtained directly or indirectly from the other Party (“Disclosing Party”)      in the course of or in anticipation of this Agreement and to respect the      Disclosing Party’s rightstherein, |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | to use the same exclusively for      the purposes of this Agreement,and |
|--------|-----|-------------------------------------------------------------------------|

|   | (c) | to disclose the same only to      those of its employees, contractors and sub-licensees pursuant to this      Agreement (if any) to whom and to the extent that such disclosure is      reasonably necessary for the purposes of this      Agreement. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 4.5 | Exceptions to      obligations. The      provisions of Clause 4.4 shall not apply to Know-how and other information      which the Receiving Party can demonstrate by reasonable, written      evidence: |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | was, prior to its receipt by the      Receiving Party from the Disclosing Party, in the possession of the      Receiving Party and at its free disposal;  or |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | is subsequently disclosed to the      Receiving Party without any obligations of confidence by a third party who      has not derived it directly or indirectly from the Disclosing Party;      or |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | is or becomes generally available      to the public through no act or default of the Receiving Party or its      agents, employees, Affiliates or  sub-Licensees. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.6 | Disclosure to      court, etc. If the      Receiving Party is required to disclose confidential information to the      courts of any competent jurisdiction, or to any government regulatory      agency or financial authority, such disclosure shall not be a breach of      Clause 4.4, provided that the Receiving Party shall (i) inform the      Disclosing Party as soon as is reasonably practicable, and (ii) at the      Disclosing Party’s request seek to persuade the court, agency or authority      to have the information treated in a confidential manner, where this is      possible under the court, agency or authority’s      procedures. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.7 | Disclosure to      employees. The      Receiving Party shall procure that all of its employees, contractors,      consultants, advisers and sub-licensees pursuant to this Agreement (if      any) who have access to any of the Disclosing Party’s information to which      Clause 4.4 applies, shall be made aware of and subject to these      obligations and shall have entered into written undertakings of      confidentiality at least as restrictive as Clauses 4.4 and 4.5 and which      apply to the Disclosing Party’s  information. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5. | Manufacturing and      supply |
|----|-------------------------------|

| 5.1 | Clinical      supply. CIMAB shall      supply to Oncoscience, and Oncoscience shall purchase from CIMAB, for its      own use and that of its Affiliates and sub-licensees, in finished form      with one hundred percent (100%) of Oncoscience’ s requirements of TheraCIM      h-R3 and Licensed Product for all clinical development purposes. Such      clinical requirements shall be supplied to    Oncoscience: |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | In respect of Oncoscience’s      requirements for clinical trials for the purposes of seeking Regulatory      Approvals in the Field in the Territory, at a supply price of US$ 500      (five hundred US dollars) per gram. Payment will be made 50% in advance      for each instalment of product that is ordered under this paragraph (a)      when it is available for delivery. The second half of payment will be paid      within 30 days after receiving the  product. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | For all other supply for clinical      purposes (including without limitation supply for Phase IV studies and for      studies that are not required for obtaining Regulatory Approvals), a      supply price equal to US$1,100 (one thousand one hundred US dollars) per      gram. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 5.2 | Commercial      Supply. |
|-----|-------------------------|

| 5.2.1 | CIMAB shall supply to      Oncoscience, and Oncoscience shall purchase from CIMAB, as active      pharmaceutical ingredient, or if the Parties mutually agree at the time of      entering into the supply agreement described in Clause 5.5, in finished      form with one hundred percent (100%) of Oncoscience’s requirements of      Licensed Products for all commercial purposes. CIMAB may elect to have      such requirements supplied to Oncoscience by one or more of CIMAB’s      Contract Manufacturer(s). In such case, the supply agreement to be entered      into shall be concluded nonetheless between Oncoscience and CIMAB and not      between Oncoscience and CIMAB’s Contract Manufacturer(s). Oncoscience’s      quantity requirements shall include those of its Affiliates and      sub-licensees. The supply price for the Licensed Product payable by      Oncoscience or its Affiliates to CIMAB (the “Supply      Price”) shall      be: |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | In the case of sales of the      Licensed Product made directly by Oncoscience or its Affiliates to a third      party other than to its sub-licensees (i) until the Payment Cap is      reached, US$ 1,250 (one thousand two hundred and fifty US dollars) per      gram of Licensed Product and (ii) after the Payment Cap is reached, as      mutually agreed to between the Parties, acting reasonably;      and |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | In the case of sales of the      Licensed Product made by Oncoscience or its Affiliates to its      sub-licensee(s), US$ 1,250 (one thousand two hundred and fifty US dollars)      per gram of LicensedProduct. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.3 | Specifications. CIMAB undertakes that all      Licensed Product supplied to Oncoscience will be manufactured in      accordance with mutually agreed upon specifications (inclusive of      specifications in an approved Marketing Authorization and Good      Manufacturing Practices of the EMEA the relevant regulatory authorities in      the other countries in the Territory, and the relevant regulatory      authorities in the countries of manufacture of the Licensed Product, and      will not be adulterated or misbranded under applicable laws, regulations      or guidelines, and that the manufacturer will have in force all necessary      Regulatory Approvals for the manufacture of Licensed Product in accordance      with such specifications for the purposes of supply and use of Licensed      Product in all countries of the Territory and will be in good standing      with all RegulatoryAuthorities. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.4 | Right to Have      Manufactured in Event of Default by  CIMAB. |
|-----|----------------------------------------------------------------|

| 5.4.1 | In the event that CIMAB or      CIMAB’s Contract Manufacturer is unwilling or unable to manufacture to the      specifications required by the relevant Regulatory Authority or by the      terms of any relevant Regulatory Approval, Oncoscience shall have the      right to have manufactured by a Third Party Manufacturer (as defined      below) one hundred percent (100%) of its own clinical and commercial      requirements of Licensed Product, in accordance with the provisions of      Clause 5.4.2. In the event that CIMAB is unable to supply Oncoscience with      its quantity requirements of Licensed Product (as described in Clause 5.1      to 5.3) for a period of one or more Calendar Quarters in any given two      year period Oncoscience shall have the right to have manufactured by a      Third Party Manufacturer as defined below its own clinical and commercial      requirements of Licensed Product, in accordance with the provisions of      Clause 5.4.2, but Oncoscience shall continue to purchase at least 50% of      its quantity requirements from CIMAB or CIMAB’s Contract Manufacturer for      as long as it is willing and able to do  so. |
|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 5.4.2 | To enable Oncoscience to have      Licensed Product manufactured for it in accordance with Clause 5.4.1, the      Parties shall, at the request of Oncoscience, make arrangements for the      transfer of relevant CIMAB manufacturing technology and know-how to a      manufacturer nominated by Oncoscience (“Third Party Manufacturer”). CIMAB      shall supply such technology and know-how free of charge but without any      obligation to bear any of Oncoscience’s costs. Prior to the transfer of      such manufacturing technology and know-how, the Third Party Manufacturer      shall be required to enter into an agreement with CIMAB, on terms      satisfactory to CIMAB, under which the Third Party Manufacturer shall      undertake to keep CIMAB’s manufacturing technology and know-how      confidential and to use it only for the supply of Licensed Product to      Oncoscience or its Affiliate or sub-licensee and only in circumstances      where Clause 5.4.1 applies. The terms of such agreement between CIMAB and      a Third Party Manufacturer shall be deemed satisfactory to CIMAB if the      terms are identical to the terms of an equivalent agreement between CIMAB      and CIMAB’s ContractManufacturer. |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.5 | Supply      Agreement. Licensed      Product supplied by CIMAB or CIMAB’s Contract Manufacturer(s) to      Oncoscience for clinical and commercial purposes shall be supplied to      Oncoscience pursuant to the terms of a separate Supply Agreement.      Oncoscience and CIMAB shall use good faith efforts to negotiate and enter      into such a supply agreement at least six (6) months prior to the      submission of a Regulatory Application for such Licensed Product in the      Territory. In addition to more detailed terms regarding form of product,      supply price, specifications, shortage of supply and default manufacturing      rights as are specified in this Clause 5, each Supply Agreement shall      contain forecast procedures, permitted variances from forecasted amounts,      order and delivery times, quality control and quality assurance      procedures, audits, yield ratios, maintenance of inventory, procedures and      remedies for rejection of non-conforming product, record retention,      compliance with laws, and other customary provisions. The terms of the      Supply Agreement shall be consistent with the provisions of this Clause 5,      unless otherwise agreed in writing by CIMAB and      Oncoscience. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6. | Grant of      rights |
|----|----------------------|

| 6.1 | Licensed      Intellectual Property. |
|-----|--------------------------------------|

| 6.1.1 | CIMYM hereby grants to      Oncoscience, subject to the provisions of this      Agreement: |
|-------|--------------------------------------------------------------------------------------------|

|   | (a) | an exclusive licence in the      Oncoscience Field and Territory (except that in Russia, Belarus and      Ukraine it shall be Co-exclusive Licence in the Field) under the Licensed      Patent Rights, with the right to sub-license, subject to Clause 6.4 below,      to develop, use and sell Licensed Product but only in the Oncoscience      Field and Territory; and |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | an exclusive licence in the      Oncoscience Field and Territory (except that in Russia, Belarus and      Ukraine it shall be Co-exclusive Licence in the Field) to use the Licensed      Know-how, with the right to sub-license, subject to Clause 6.4 below, to      develop, use and sell Licensed Product but only in the Oncoscience Field      and Territory; and |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | an exclusive licence in the      Oncoscience Field and Territory (except that in Russia, Belarus and      Ukraine it shall be Co-exclusive Licence in the Field) to have Licensed      Product manufactured for it by a Third Party Manufacturer, but only in the      circumstances described in Clause5.4. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 6.1.2 | In the event that CIMAB wishes to      exercise its Co-exclusive rights in Russia, Belarus or Ukraine, it shall      notify Oncoscience of its intended activities in such countries, in      particular to ensure that Oncoscience’s rights under this Agreement are      not adversely affected. |
|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.2 | Arising      Intellectual Property (including clinical  data). |
|-----|----------------------------------------------------------------|

| 6.2.1 | Arising Intellectual Property      shall be owned by the Party (which for the purposes of this clause may      include CIM) that invents or creates it, and if it is jointly invented or      created by two or more of the Parties it shall be owned jointly by those      Parties in equal, undivided shares, subject to the provisions of this      Agreement including the following  provisions: |
|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | Recognising the contribution that      CIM’s scientists have made, and are continuing to make, to the development      of TheraCIM h-R3 and the current stage of its development, the Parties      anticipate that, as a matter of law, CIM scientists should be named as      inventor(s) or joint inventor(s) of any new inventions made under this      Agreement. Accordingly, unless the Party filing a patent application in      respect of Arising Intellectual Property is advised by external patent      counsel that such naming would prejudice the validity of the resulting      Arising Patents, all Arising Patents shall be considered to have been      jointly invented by representatives of CIM and Oncoscience, and      accordingly shall be jointly owned by them in equal, undivided shares,      subject to the provisions of this  Agreement; |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | It is anticipated that Arising      Know-how will be generated by clinicians and other Persons in the course      of, or arising from, clinical studies that have been designed by the Joint      Development Team. Accordingly, it is agreed that all Arising know-how      developed in, or arising from, the work performed under the Development      and Commercialisation Plan shall be jointly owned by CIM and Oncoscience      in equal, undivided shares, subject to the provisions of this Agreement;      and |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | Subject to paragraphs (a) and (b)      above, where Arising Intellectual Property consists of an improvement to,      or a new application of, Licensed Intellectual Property and, as a matter      of law, is made solely by employees of Oncoscience, it shall be owned      solely by Oncoscience. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.2.2 | CIMAB hereby grants and agrees to      grant to Oncoscience an exclusive, fully paid-up and royalty-free licence      under Arising Intellectual Property in the Oncoscience Field and      Territory, with the right to sub-license, to research, develop, make, have      made, import, use, sell and otherwise deal in any and all products and      processes in the Oncoscience Field and  Territory. |
|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.2.3 | Oncoscience hereby grants and      agrees to grant to CIMYM and CIMAB an exclusive, fully paid-up and      royalty-free licence under Arising Intellectual Property in the CIMYM      Field and Territory, with the right to sub-license, to research, develop,      make, have made, import, use, sell and otherwise deal in any and all      products and processes in the CIMYM Field and      Territory. |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.3 | Formal      licences. If      requested by Oncoscience, and at Oncoscience’s administrative cost, the      Parties shall execute such formal licences as may be necessary or      appropriate for registration with Patent Offices and other relevant      authorities in the Territory. In the event of any conflict in meaning      between any such licence and the provisions of this Agreement, the      provisions of this Agreement shall prevail. The Parties shall use      reasonable endeavours to ensure that, to the extent permitted by relevant      authorities, this Agreement shall not form part of any public      record. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 6.4 | Sub-licensing. Oncoscience shall be entitled      to grant sub-licences (which for the purposes of this clause shall include      any option or right to acquire a sub-licence) of its rights under this      Agreement to any person (including without limitation any Affiliate of      Oncoscience), provided that: |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | Oncoscience shall first provide      written notice to CIMYM of any request to enter into a sub-license and      shall provide with such notice a copy of the proposed sub-license      agreement. CIMYM shall provide its response to any such request within      thirty (30) days of its receipt of Oncoscience’s notice, failing which, it      shall be deemed to have consented to such request. CIMYM shall have no      reason to withhold its consent to such request provided that the proposed      sub-license agreement complies with the terms of this Clause 6.4.      Oncoscience shall provide to the Parties, within thirty (30) days of its      execution, a fully executed copy of the sub-license      agreement; |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | the scope of the sub-licence      shall not exceed the scope of the licence granted under this Agreement      and, in particular, shall not include any manufacturing      rights; |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | the sub-licence shall include      obligations on the sub-licensee which are equivalent to the obligations on      Oncoscience under this Agreement (and the sub-licensee shall not have any      right to grant sub-sub-licences without CIMYM’s prior written agreement,      which consent may be withheld at CIMYM’s sole      discretion); |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (d) | if agreed between CIMYM and the      sub-licensee, the sub-licence shall continue in force as an agreement      between CIMYM (in place of Oncoscience) and the sub-licensee or, if no      such agreement is made, the sub-licence shall terminate automatically on      the termination of this Agreement for any  reason; |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (e) | clinical trials in the territory      of the sub-licensee shall commence not later than 18 months from the date      of the conclusion of the sub-licence agreement, failing which the      sub-licence shall automatically  terminate; |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (f) | Oncoscience shall have no      ownership interest of any kind in the proposed sub-licensee;      and |
|--------|-----|------------------------------------------------------------------------------------------------------|

|   | (g) | Oncoscience shall be responsible      for any breach of the sub-licence by the sub-licensee, as if the breach      had been that of Oneoscience under this Agreement, and Oncoscience shall      indemnify CIMYM against any loss, damages, costs, claims or expenses which      are awarded against or suffered by CIMYM as a result of any such breach by      the sub-licensee. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.5 | Reservation      of rights within Field and Territory. For the avoidance of doubt,      CIMYM reserves the right for itself and its licensees and assigns to use      TheraCIM h-R3 and the Licensed Intellectual Property in the Oncoscience      Field and Territory with the prior consent of Oncoscience (a) for the      purposes of research; and/or (b) for the purposes of development      (including clinical trials) of products with a view to obtaining      regulatory approval for such products in the CIMYM Field and Territory. If      CIMYM wishes to conduct research or development activities in the      Oncoscience Field and Territory in accordance with the provisions of this      clause, it will so inform Oncoscience and give Oncoscience a first      opportunity to propose terms for an agreement with CIMYM under which      Oncoscience would assist CIMYM with such activities at the cost of CIMYM.      It is understood and agreed that CIMYM will be required under regulatory      GCP to retain archive samples of  materials. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 6.6 | No other      licence. It is      acknowledged and agreed that no licence is granted by CIMYM to Oncoscience      other than the licence(s) expressly granted by the provisions of this      Clause 6. Without prejudice to the generality of the foregoing CIMYM      reserves all rights under the Licensed Intellectual Property in the CIMYM      Field and Territory. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.7 | Quality. Oncoscience shall ensure that      all Licensed Product marketed by it and its sub-licensees is of      satisfactory quality and complies with all applicable laws and regulations      in each part of theTerritory. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.8 | Acknowledgment      by CIMAB. CIMAB      acknowledges and agrees that CIMYM has been granted the necessary rights      and licences to enable it to grant the licences referred to in Clauses      6.1. and 6.4 of thisAgreement. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.9 | Acknowledgment      by CIMYM and CIMAB.      CIMYM and CIMAB acknowledge and agree that, subject to Clause 6.4(g),      Oncoscience is free to organize its distribution of the Licensed Product      and determine its sales price of the Licensed Product within the      Oncoscience Field and Territory at its own discretion. Oncoscience is also      free to determine its sales price vis-à-vis its sub-licensees. However,      only for the purpose of calculating the royalties pursuant to Article 7 of      this Agreement the supply price charged by Oncoscience to its      sub-licensees shall be deemed $ 2,312.50 (two thousand three hundred and      twelve US dollars and fifty cents) per gram if and as far as Oncoscience      charges a supply price to its sub-licensees which is below the threshold      of $ 2,312.50 (two thousand three hundred and twelve US dollars and fifty      cents) per gram. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7. | Payments |
|----|----------|

| 7.1 | Payments      prior to reaching Payment Cap. Until such time as the total      amount of payments made by Oncoscience to CIMYM under this Clause 7.1      reaches US$30,000,000 (thirty million US dollars) (excluding VAT or      other taxes or charges and excluding the amount of any payments from      Oncoscience to CIMYM in respect of the supply of products, materials or      services) (the “Payment Cap”), Oncoscience shall pay to CIMYM the      following amounts: |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | *% (* percent) of all Milestone      Receipts, which shall be payable within 30 (thirty) days of any such      Milestone Receipt being received by Oncoscience or its      Affiliate; |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | In the case of sales of the      Licensed Product made directly by Oncoscience or its Affiliates to a third      party other than itssub-licensee(s): |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (i) | a royalty of *% (* percent) of      Net Sales Value of all Licensed Product;  and |
|--------|-----|-----------------------------------------------------------------------------------|

|   | (ii) | an additional royalty of US$* (*      US dollars) per gram of the Licensed Product;  and |
|--------|------|------------------------------------------------------------------------------------------|

----

|   | (c) | In the case of sales of the      Licensed Product made by Oncoscience or its Affiliates to its      sub-licensee(s), a royalty of *% of Net Sales Value of all Licensed      Product. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.2 | Payments      after reaching Payment Cap. |
|-----|-------------------------------------------|

| 7.2.1 | Royalties. After the total amount of      payments made by Oncoscience to CIMYM under Clause 7.1 has reached the      Payment Cap, Oncoscience shall pay to CIMYM the following      amounts: |
|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | *% (* percent) of all Milestone      Receipts, which shall be payable within 30 (thirty) days of any such      Milestone Receipt being received by Oncoscience or its      Affiliates; |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | In the case of sales of the      Licensed Product made directly by Oncoscience or its Affiliates to a third      party other than its sub-licensee(s), a royalty on cumulative Gross Sales      Value of Licensed Product in each Calendar Year, at the following      incremental rates: |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Incremental Gross Sales Value in Calendar Year |   | Royalty rate |   |
|------------------------------------------------------------------------------|--------|-------------------|--------|
| Less      than or equal to US$*M                                             |   |              | *      | % |
| Greater      than US$*M and less      than or equal to US$*M                 |   |              | *      | % |
| Greater      than US$*M and less      than or equal to US$*M                 |   |              | *      | % |
| Greater      than US$*M                                                      |   |              | *      | % |

| (i)   | *%      on the first US$*M of Gross Sales Value =    |   | US$ | *M |    |
|-------|------------------------------------------------------|--------|-----|----|---------|
| (ii)  | *%      on the next US$*M of Gross Sales Value =     |   | US$ | *M |    |
| (iii) | *%      on the remaining US$*M of Gross Sales Value= |   | US$ | *M |    |
| (iv)  | Total      amount of royalty due in Calendar Year =  |   | US$ | *M | ;  |

|   | (c) | In the case of sales of the      Licensed Product made by Oncoscience or its Affiliates to its      sub-licensee(s), a royalty of *% of Net Sales Value of all Licensed      Product. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.3 | Payment      dates. Royalties due      under this Agreement shall be paid within 90 days of the end of each      Calendar Quarter, in respect of sales of Licensed Product made during such      Calendar Quarter, and within 120 days of the termination of this      Agreement. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.4 | Payment      terms. All sums due      under this Agreement: |
|-----|-------------------------------------------------------------|

|   | (a) | are exclusive of Value Added Tax      which where applicable will be paid by Oncoscience to CIMYM in      addition; |
|--------|-----|---------------------------------------------------------------------------------------------------------------------|

|   | (b) | shall be paid in US dollars (or      such other currency as the Parties may agree) and, in the case of sales or      sub-license income received by Oncoscience in a currency other than US      dollars, the income shall be calculated in the other currency and then      converted into equivalent US dollars at the purchasing rate for US dollars      as      quoted by Kreissparkasse Sűdholstein, Friedrich-Ebert-Damm 38-40 25431      Pinneberg in Germany as at the close of business on the last business day      of the quarterly period with respect to which the payment is      made; |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | (c) | shall be made without deduction      of income tax or other taxes charges or duties that may be imposed, except      insofar as Oncoscience is required to deduct the same to comply with      applicable laws. The Parties shall cooperate and take all steps reasonably      and lawfully available to them to avoid deducting such taxes and to obtain      double taxation relief. If Oncoscience is required to make any such      deduction it shall provide CIMYM with such certificates or other documents      as it can reasonably obtain to enable CIMYM to obtain appropriate relief      from double taxation of the payment in question;  and |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (d) | shall be made by the due date,      failing which CIMYM may charge interest on any outstanding amount on a      daily basis at a rate equivalent to 3% above the US prime lending rate      then in force. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.5 | Exchange      controls, etc. If at      any time during the continuation of this Agreement Oncoscience is      prohibited from making any of the payments required hereunder by a      governmental authority in any country then Oncoscience will within the      prescribed period for making the said payments in the appropriate manner      use its best endeavours to secure from the proper authority in the      relevant country permission to make the said payments and will make them      within 7 days of receiving such permission. If such permission is not      received within 30 (thirty) days of Oncoscience making a request for such      permission then, at the option of CIMYM, Oncoscience shall deposit the      royalty payments due in the currency of the relevant country either in a      bank account designated by CIMYM within such country or such royalty      payments shall be made to an associated company of CIMYM designated by      CIMYM and having offices in the relevant country designated by      CIMYM. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.6 | Royalty      statements.      Oncoscience shall send to CIMYM at the same time as each royalty payment      is made in accordance with Clause 7.3 a statement setting out, in respect      of each country in which Licensed Product is sold, the types of Licensed      Product sold, the quantity of each type sold, and the total Gross Sales      Value and Net Sales Value, in respect of each type, expressed both in      local currency and US dollars and showing the conversion rates used,      during the period to which the royalty payment    relates. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.7 | Records |
|-----|---------|

| 7.7.1 | Oncoscience shall keep at its      normal place of business detailed and up to date records and accounts      showing the quantity, description and Gross Sales Value of Licensed      Product, all the documents corresponding to the deductions, and the amount      of Milestone Receipts received by it in respect of Licensed Product, on a      country by country basis, and being sufficient to ascertain the payments      due under this Agreement. |
|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.7.2 | Oncoscience shall make such      records and accounts available, on reasonable notice, for inspection      during business hours by an independent chartered accountant nominated by      CIMYM for the purpose of verifying the accuracy of any statement or report      given by Oncoscience to CIMYM under Clause 7.6. The accountant shall be      required to keep confidential all information learnt during any such      inspection, and to disclose to CIMYM only such details as may be necessary      to report on the accuracy of Oncoscience’s statement or report. CIMYM      shall be responsible for the accountant’s charges unless the accountant      certifies that there is an inaccuracy of more than 5% (five percent) in      any royalty statement, in which case Oncoscience shall pay his charges in      respect of that inspection. If the inspection shows that Oncoscience owes      a payment to CIMYM under this Agreement, Oncoscience shall promptly make      such payment. |
|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 7.7.3 | Oncoscience shall ensure that      CIMYM has the same rights as those set out in this Clause 7.7 in respect      of any Affiliate or sub-licensee of Oncoscience that is sub-licensed under      Licensed Intellectual Property pursuant to this      Agreement. |
|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8. | Diligence |
|----|-----------|

| 8.1 | Oncoscience shall use Diligent      and Reasonable Efforts to develop and commercially exploit Licensed      Product to the maximum extent throughout the Territory. Without limiting      Oncoscience’s obligations under the previous sentence of this Clause 8.1,      Oncoscience shall develop and commercially exploit Licensed Product in      accordance with the Development and Commercialisation      Plan. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.2 | If CIMYM considers at any time      during the period of this Agreement that Oncoscience has without      legitimate reason failed to comply with its obligations under Clause 8.1,      CIMYM shall be entitled to refer to an independent expert the following      questions: |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | whether Oncoscience has complied      with such obligations; and ifnot |
|--------|-----|------------------------------------------------------------------------|

|   | (b) | what specific action Oncoscience      should have taken (“Specific Action”) in order to have so      complied. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------|

| 8.3 | The independent expert shall be      appointed in accordance with the provisions of Schedule 4 and his decision      shall be final and binding on the  Parties. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.4 | If the expert determines that      Oncoscience has failed to comply with its obligations under this Clause 8,      and if Oncoscience fails to take the Specific Action within 6 months of      the expert giving his decision in accordance with Schedule 4, CIMYM shall      be entitled, by giving, at any time within 3 months after the end of that      6 month period, not less than 3 months’ notice to terminate this Agreement      and the licences granted to Oncoscience under Clause    6. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9. | Intellectual      property |
|----|----------------------------|

| 9.1 | Obtain and      maintain the Licensed Patent Rights. CIMYM shall, at its cost and      expense: |
|-----|-------------------------------------------------------------------------------------------------|

|   | (a) | Diligently seek to obtain valid      patents in the name of CIM pursuant to each of the patent applications      listed in Schedule 1; and |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | pay all renewal fees in respect      of the Licensed Patent Rights as and when  due; |
|--------|-----|--------------------------------------------------------------------------------------|

| 9.2 | Obtain and      maintain the Arising Patents. The Parties shall consult with      one another in relation to the filing and maintenance of any Arising      Patents in respect of any inventions made by Oncoscience, its Affiliates      or sub-licensees that relate to any of the Licensed Intellectual Property      or the Licensed Product (“Arising Inventions”). Oncoscience shall or shall      ensure that its Affiliate or sub-licensee shall, at its own cost and      expense: |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | (a) | Diligently seek to obtain valid      patents (in the name of the relevant Parties as specified in Clause 6.2.1)      in respect of any Arising Inventions;and |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | pay all renewal fees in respect      of the Arising Patents as and whendue; |
|--------|-----|-----------------------------------------------------------------------------|

| 9.3 | Infringement      of the Patents |
|-----|----------------------------------|

| 9.3.1 | Each Party shall inform the other      Party promptly if it becomes aware of any infringement or potential      infringement of any of the Patents in the Oncoscience Field and Territory,      and the Parties shall consult with each other to decide the best way to      respond to suchinfringement. |
|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.3.2 | Oncoscience shall be responsible,      at its discretion, for taking action against infringers of the Licensed      Patents in the Oncoscience Field and Territory at its sole expense, and it      shall be entitled to retain any damages or other payments or benefits      obtained by such action in the Oncoscience Field and Territory, after      reimbursing CIMYM and CIMAB for any reasonable expenses incurred in      assisting it in such action. If Oncoscience declines to take action, then      CIMYM shall be entitled to take action against the third party at CIMYM’s      sole expense and CIMYM shall be entitled to all damages or other sums      received from such action, after reimbursing Oncoscience for any      reasonable expenses incurred in assisting it in such action. If the      alleged infringement is both within and outside the Oncoscience Field and      Territory, the Parties shall also co-operate with CIMYM’s and CIMAB’s      other licensees (if any) in relation to any such action and shall divide      the costs of such action proportionately among Oncoscience and CIMYM’s and      CIMAB’s other licensees who participate in such action. The apportionment      of costs between licensees shall be decided by CIMYM, acting      reasonably. |
|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.4 | Infringement      of third party rights |
|-----|-----------------------------------------|

| 9.4.1 | If any warning letter or other      notice of infringement is received by a Party, or legal suit or other      action is brought against a Party, alleging infringement of third party      rights in the manufacture, use or sale of the Licensed Product or use of      any Patents, that Party shall promptly provide full details to the other      Party, and the Parties shall discuss the best way to      respond. |
|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.4.2 | CIMYM shall have the right but      not the obligation to defend such suit and shall have the right to settle      with such third party, provided that if any action or proposed settlement      involves the making of any statement, express or implied, concerning the      validity of any Patent, the consent of Oncoscience must be obtained before      taking such action or making such settlement, such consent not to be      unreasonably withheld ordelayed. |
|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 9.5 | Third party      intellectual property. For the avoidance of doubt      Oncoscience shall be solely responsible for obtaining and paying for any      additional licences and other rights that may be required to enable      Oncoscience, its Affiliates or sub-licensees to commercialise Licensed      Product in the Territory. If the sale of TheraCIM h-R3 is found to      infringe the intellectual property rights of a third party, and results in      the payment of royalties or other compensation by Oncoscience (or its      Affiliate or sub-licensee) to the third party, Oncoscience may reduce its      royalty payments to CIMYM, the reduction to be in the amount of *% (*      percent) of the royalties or other compensation paid to the third party in      respect of sales of Licensed Product in the Territory, subject to the      following conditions: |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | The reduction shall not exceed *%      (* percent) of Net Sales Value with respect to the country(ies) in the      Territory for which payments are being made to the third party. For      example, if in the absence of this Clause the royalty due from Oncoscience      to CIMYM on the sale of a Licensed Product is *% (* percent) of Net Sales      Value, the royalty following such deduction shall not be reduced below *%      (* percent). |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | Such reductions shall only be      made where the third party liability arises from the use of the inventions      claimed in the Licensed Patents and shall not be made in respect of any      other inventions, improvements or other features that Oncoscience chooses      to incorporate into the LicensedProduct. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.6 | Product      names. Oncoscience      shall be responsible for deciding, in consultation with CIMYM, the trade      mark to be applied to the Licensed Product in the Oncoscience Field and      Territory. Oncoscience will be responsible for applying for any such trade      mark in the Territory at its sole cost. CIMYM acknowledges that it has no      objection against the trade mark “Theraloc”. CIMYM will be responsible for      applying for an international, non-proprietary name (“INN”) for the      Licensed Product at its sole cost. Oncoscience acknowledges that it has no      objection to the INN“CIMAZUMAB”. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10. | Warranties and      liability |
|-----|-------------------------------|

| 10.1 | Warranties by      CIMYM. CIMYM      warrants that: |
|------|-----------------------------------------------------|

|   | (a) | subject to Clause 10.4, it is the      owner or exclusive licensee of the Licensed Patent Rights;      and |
|--------|-----|------------------------------------------------------------------------------------------------------------|

|   | (b) | it has not done, and will not do      nor agree to do during the continuation of this Agreement, any of the      following things if to do so would be inconsistent with the exercise by      Oncoscience of the rights granted to it under this Agreement,      namely: |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (i) | grant or agree to grant any      rights in the Licensed Patent Rights in the Oncoscience Field and      Territory; or |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------|

|   | (ii) | assign, mortgage, charge or      otherwise transfer any of the Licensed Patent Rights;      and |
|--------|------|-------------------------------------------------------------------------------------------------|

|   | (c) | it is not aware (but without      having carried out any searches or investigations) that any third party      (other than CIMYM’s licensor(s)) owns or claims any rights in the Licensed      Patent Rights. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 10.2 | Warranty by      Oncoscience.      Oncoscience warrants and undertakes (a) that it has, and will continue to      have sufficient financial and other resources to fulfil its obligations      under this Agreement, and (b) that it has obtained all necessary      authorisations from its supervisory board and investors to use such      resources and fulfil suchobligations. |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.3 | No other      warranties |
|------|--------------------------|

| 10.3.1 | Each of Oncoscience and CIMYM      acknowledges that, in entering into this Agreement, it does not do so in      reliance on any representation, warranty or other provision except as      expressly provided in this Agreement, and any conditions, warranties or      other terms implied by statute or common law are excluded from this      Agreement to the fullest extent permitted by  law. |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.3.2 | Without limiting the scope of      Clause 10.3.1, CIMYM does not give any warranty, representation or      undertaking:- |
|--------|--------------------------------------------------------------------------------------------------------------------------|

|   | (a) | as to the efficacy or usefulness      of any of the Licensed Intellectual Property;  or |
|--------|-----|-----------------------------------------------------------------------------------------|

|   | (b) | that any of the Licensed Patent      Rights is or will be valid or subsisting or (in the case of an      application) will proceed to grant;or |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | that the use of any of the      Licensed Intellectual Property, the manufacture, sale or use of the      Licensed Product or the exercise of any of the rights granted under this      Agreement will not infringe any other intellectual property or other      rights of any other person;or |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (d) | that the Licensed Know-how or any      other information or materials communicated or provided by CIMYM to      Oncoscience under or in connection with this Agreement will produce      Licensed Product of satisfactory quality or fit for the purpose for which      Oncoscience intended; or |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (e) | as imposing any obligation on      CIMYM to bring or prosecute actions or proceedings against third parties      for infringement or to defend any action or proceedings for revocation of      any of the Licensed Patent Rights;or |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (f) | as imposing any liability on      CIMYM in the event that any third party supplies Licensed Product to      customers located in theTerritory. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.4 | Indemnity and      insurance.      Oncoscience shall indemnify and hold harmless CIMYM and (except as      otherwise provided in any Supply Agreement) CIMAB and their respective      Affiliates and their respective officers, employees, consultants, agents      and representatives (the “Indemnitees”) against all third party Claims      which may be asserted against or suffered by any of the Indemnitees and      which relate to: |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | the use of any Delivered Items;      or |
|--------|-----|-----------------------------------------|

|   | (b) | the manufacture, distribution,      sale, supply or use of the Licensed Product or any other products or      services which incorporate any Delivered  Items, |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 10.5 | Liability. Subject to Clause 10.4, but      notwithstanding any other provision of this Agreement, no Party shall be      liable to any other Party to this Agreement in contract, tort, negligence,      breach of statutory duty or otherwise for any loss, damage, costs or      expenses of any nature whatsoever incurred or suffered by that other party      or its Affiliates of an indirect or consequential nature including without      limitation any economic loss or other loss of turnover, profits, business      or goodwill. |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11. | Duration and      Termination |
|-----|-------------------------------|

| 11.1 | Commencement      and Termination by Expiry. This Agreement, and the      licences granted hereunder, shall come into effect on the Commencement      Date and, unless terminated earlier in accordance with this Clause 11,      shall continue in force on a country by country basis in the Territory      until the latest of: |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | The date on which all the      Licensed Patents have expired or been revoked in that country without a      right of further appeal, and |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | The date on which any Orphan Drug      Status for Licensed Product in that country has expired;      and |
|--------|-----|----------------------------------------------------------------------------------------------------------|

|   | (c) | The tenth anniversary of the date      of the first commercial sale of Licensed Product in that country by      Oncoscience, its Affiliate or sub-licensee or, if that country is part of      the European Union, the tenth anniversary of the date of the first      commercial sale of the Licensed Product in the European Union by      Oncoscience, its Affiliate or  sub-licensee; |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.2 | Early      termination |
|------|------------------------|

| 11.2.1 | Oncoscience may terminate this      Agreement at any time on 90 days notice in writing to      CIMYM. |
|--------|-------------------------------------------------------------------------------------------------------|

| 11.2.2 | Without prejudice to any other      right or remedy, either of CIMYM or Oncoscience may terminate this      Agreement at any time by notice in writing to the other of them (“Other      Party”), such notice to take effect as specified in the      notice: |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | if the Other Party (which in the      case of Oncoscience shall include any Affiliate or sub-licensee of      Oncoscience) is in material breach of this Agreement and, in the case of a      breach capable of remedy within 90 days, the breach is not remedied within      90 days of the Other Party receiving notice specifying the breach and      requiring its remedy; or |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | if the Other Party (which in the      case of Oncoscience shall include any Affiliate or sub-licensee of      Oncoscience) becomes insolvent, or if an order is made or a resolution is      passed for the winding up of the Other Party (other than voluntarily for      the purpose of solvent amalgamation or reconstruction), or if an      administrator, administrative receiver or receiver is appointed in respect      of the whole or any part of the Other Party’s assets or business, or if      the Other Party makes any composition with its creditors or takes or      suffers any similar or analogous action in consequence of debt;      or |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | (e) | if the first Phase II clinical      trial for the Licensed Product in the Field in the Territory has not      commenced within a period of two years after the Commencement Date;      or |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (d) | if the first Regulatory Approval      for marketing the Licensed Product in the Field in the Territory is not      obtained within a period of five years after the Commencement      Date. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.2.3 | CIMYM may forthwith terminate      this Agreement by giving written notice to Oncoscience if Oncoscience or      its Affiliate or sub-licensee commences legal proceedings, or assists any      third party to commence legal proceedings, to challenge the validity of      any of the Patents. |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.2.4 | The Parties acknowledge and agree      that Oncoscience’s remedy for any breach by CIMAB of its obligations under      Clause 5 shall be as set out in Clause 5.4 or in any Supply Agreement that      CIMAB and Oncoscience may execute pursuant to Clause 5.5. Accordingly,      breach of Clause 5 shall not entitle any Party to terminate this      Agreement. |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.3 | Consequences      of termination |
|------|----------------------------------|

| 11.3.1 | Upon termination of this      Agreement for any reason otherwise than in accordance with Clause      11.1: |
|--------|------------------------------------------------------------------------------------------------------------|

|   | (a) | If termination occurs afler the      first commercial sale of Licensed Product, Oncoscience and its      sub-licensees shall be entitled to sell, use or otherwise dispose of      (subject to payment of royalties under Clause 7.1 or 7.2) any unsold or      unused stocks of the Licensed Product for a period of 6 months following      the date of termination; and if termination occurs prior to the first      commercial sale of Licensed Product, Oncoscience shall forthwith return      all such stocks of Licensed Product and Licensed Know-how to CIMYM free of      charge; |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | subject to paragraph (a) above,      Oncoscience shall no longer be licensed to use or otherwise exploit in any      way, either directly or indirectly, any of the Licensed Intellectual      Property; |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | subject to paragraph (a) above,      Oncoscience shall consent to the cancellation of any formal licence      granted to it, or of any registration of it in any register, in relation      to any of the Licensed PatentRights; |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (d) | the provisions of the following      clauses shall continue in force without limit of time, except that the      continuing obligations under Clause 4, referred to in paragraph (i) below,      shall survive for a period of 5 years from the termination of this      Agreement: |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (i) | Clauses 4.3 (except that      Oncoscience shall not have any continuing right to use Licensed Know-how      or any other information received from CIMYM or CIMAB), 4.4(a) (subject to      Clause 4.5) (and no further disclosure may be made by Oncoscience under      Clause 4.7); |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | (ii) | Clause 7 (in respect of sales of      Licensed Product made prior to termination, or after termination under the      first part of Clause 11.3.1(a));and |
|--------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (iii) | Clause 10.3 and 12;      and |
|--------|-------|------------------------------|

|   | (e) | subject as provided in this      Clause 11.3.1 and 11.3.2, and except in respect of any accrued rights,      neither Party shall be under any further obligation to the      other. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.3.2 | Upon termination of this      Agreement for any reason otherwise than in accordance with Clause 11.1 and      at CIMYM’s request, Oncoscience shall, without charge to, or other      obligation on the part of,CIMYM: |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | transfer to CIMYM exclusively all      clinical and other data relating to the development of Licensed      Product; |
|--------|-----|----------------------------------------------------------------------------------------------------------------------|

|   | (b) | to the extent possible, seek to      have any Regulatory Approvals (including without limitation product      licences and pricing approvals) and other permits and applications      transferred into the name of CIMYM or its  nominee; |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | grant CIMYM an exclusive,      worldwide licence, with the rights to grant sub-licences, under all      Arising Intellectual Property and any improvements and other intellectual      property owned or controlled by Oncoscience relating to Licensed Product;      and |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (d) | grant CIMYM or its nominee the      right to continue to use any product name that had been applied to the      Licensed Product prior to termination of this      Agreement. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12. | General |
|-----|---------|

| 12.1 | Force      majeure. Neither      Party shall have any liability or be deemed to be in breach of this      Agreement for any delays or failures in performance of this Agreement      which result from circumstances beyond the reasonable control of that      Party, including without limitation labour disputes involving that Party.      The Party affected by such circumstances shall promptly notify the other      Party in writing when such circumstances cause a delay or failure in      performance and when they cease to doso. |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.2 | Language and      Amendment. This      Agreement is made in the English language and may only be amended in the      English language in writing signed by duly authorised representatives of      the Parties. In the event of any conflict in meaning between the English      language version and any translation of this Agreement, the English      language version shallprevail. |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.3 | Assignment      and third party rights. |
|------|-----------------------------------------|

| 12.3.1 | Subject to Clause 12.3.2 below,      no Party shall assign, mortgage, charge, or otherwise transfer any rights      or obligations under this Agreement, nor any of the Patents or rights      under the Patents, without the prior written consent of the      Parties. |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 12.3.2 | With the prior written consent of      the other Parties, a Party may assign all its rights and obligations under      this Agreement together with its rights in the Patents to any company to      which it transfers all or substantially all of its assets or business in      the Field, provided that the assignee undertakes to the other Party to be      bound by and perform the obligations of the assignor under this      Agreement. |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.4 | Waiver. No failure or delay on the part      of either Party to exercise any right or remedy under this Agreement shall      be construed or operate as a waiver thereof, nor shall any single or      partial exercise of any right or remedy preclude the further exercise of      such right or remedy. |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.5 | Invalid      clauses. If any      provision or part of this Agreement is held to be invalid, amendments to      this Agreement may be made by the addition or deletion of wording as      appropriate to remove the invalid part or provision but other wise retain      the provision and the other provisions of this Agreement to the maximum      extent permissible under applicablelaw. |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.6 | No      Agency. Neither      Party shall act or describe itself as the agent of the other, nor shall it      make or represent that it has authority to make any commitments on the      other’s behalf. |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.7 | Interpretation. In this      Agreement: |
|------|-----------------------------------------|

|   | (a) | the headings are used for      convenience only and shall not affect its      interpretation; |
|--------|-----|-----------------------------------------------------------------------------------------------|

|   | (b) | references to persons shall      include incorporated and unincorporated persons; references to the      singular include the plural and vice versa; and references to the      masculine include thefeminine; |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | references to Clauses and      Schedules mean clauses of, and schedules to, this      Agreement; |
|--------|-----|--------------------------------------------------------------------------------------------------|

|   | (d) | references to any Party shall      include their permitted successors and permitted      assignees; |
|--------|-----|-----------------------------------------------------------------------------------------------------|

|   | (e) | references to any licence shall      mean, where the context requires, a  sub-licence; |
|--------|-----|----------------------------------------------------------------------------------------|

|   | (f) | where the word “including” is      used, it shall be understood as meaning “including without limitation”;      and |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------|

|   | (g) | references to the grant of      “exclusive” rights shall mean that the person granting the rights shall      neither grant the same rights (in the same Field and Territory and in      respect of the same Licensed Product) to any other person, nor exercise      those rights directly to the extent that and for as long as the Licensed      Product is within Valid Claims of unexpired Licensed Patent Rights or, to      the extent that the Licensed Product is protected by Licensed Know-how      that have not become known and available to the public, for a period of 10      years from the first commercial sale of Licensed Product in any part of      the Territory. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.8 | Notices |
|------|---------|

| 12.8.1 | Any notice to be given under this      Agreement shall be in writing and shall be sent by first class mail, air      mail or by courier, or by fax (confirmed by first class mail or air mail)      to the address of the relevant Party set out at the head of this      Agreement, or to the relevant fax number set out below, or such other      address or fax number as that Party may from time to time notify to the      other Party in accordance with this Clause 12.8. The fax numbers of the      Parties are as follows: |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| Party       |   | Fax      number         |
|-------------|--------|-------------------------|
|        |   |                    |
| CIMYM       |   | 001      905 629 4959   |
| CIMAB       |   | 0053      7273 3509     |
| Oncoscience |   | 0049      4103 1808 820 |

| 12.8.2 | Notices sent as above shall be      deemed to have been received three working days after the day of posting      (in the case of inland first class mail or national courier), or seven      working days after the date of posting (in the case of air mail or      international courier), or on the next working day after transmission (in      the case of fax messages, but only if a transmission report is generated      by the sender’s fax machine recording a message from the recipient’s fax      machine, confirming that the fax was sent to the number indicated above      and confirming that all pages were successfully      transmitted). |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.9 | Law and      Jurisdiction. The      validity, construction and performance of this Agreement shall be governed      by English law. Any dispute arising out of or in connection with this      Agreement, including any question regarding its existence, validity or      termination, shall be referred to and finally resolved by arbitration by a      single arbitrator in London under the Rules of the London Court of      International Arbitration (the “Rules”), which Rules are deemed to be      incorporated by reference into this clause. The language to be used in the      arbitral proceedings shall be English. The arbitrator shall be chosen by      the Parties or, failing agreement as to the choice of arbitrator within 28      days of one Party requesting that an arbitrator by chosen, appointed in      accordance with the Rules. However, nothing in this Agreement shall      prevent a Party from seeking an interim injunction in any court of      competent jurisdiction. |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.10 | Further      action. Each Party      agrees to execute, acknowledge and deliver such further instruments, and      do all further similar acts, as may be necessary or appropriate to carry      out the purposes and intent of this  Agreement. |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.11 | Announcements. Neither Party shall make any      press or other public announcement concerning any aspect of this      Agreement, or make any use of the name of the other Party in connection      with or in consequence of this Agreement, without the prior written      consent of the other Party, except as may be required by law or by the      rules of any stock exchange on which either Party is listed. The Parties      shall agree a form of press release for issue on signature of this      Agreement. |
|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.12 | Entire      agreement. This      Agreement, including its Schedules, sets out the entire agreement between      the Parties relating to its subject matter and supersedes all prior oral      or written agreements, arrangements or understandings between them      relating to such subject matter. The Parties acknowledge that they are not      relying on any representation, agreement, term or condition that is not      set out in this Agreement. Nothing in this Agreement excludes liability      for fraud. |
|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.13 | Third party      rights. Each of the      persons identified as Indemnitees in Clause 10.4 may in his own right      enforce the provisions of those respective Clauses. Except as provided in      the previous sentence of this Clause 12.12, this Agreement is not made for      the benefit of, nor shall any of its provisions be enforceable by, any      person other than the parties to this Agreement and their respective      successors and permittedassignees. |
|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 12.14 | Non-compete. Oncoscience warrants,      represents, acknowledges and agrees, in respect of it and its Affiliates      that: |
|-------|-----------------------------------------------------------------------------------------------------------------------------|

|   | (a) | they do not have any interest in      any technology that competes with the Licensed Intellectual Property, nor      is any of them engaged in any research or development activities with      respect to any product that would compete with the Licensed Products;      and |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | for as long as this Agreement      remains in force, they will not enter into any agreement with any Person      other than CIMAB or CIMYM for the development or marketing of any product      that is, or contains, (i) any other anti-EGF-receptor inhibitor, (ii) any      product or component or sequence of EGF-R, EGF-R ligands, or any small      tyrosine kinase inhibitor. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.15 | Amendment and      Restatement. The      Original Agreement is hereby terminated. This Agreement supersedes, and      amends and restates the Original  Agreement. |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| [ILLEGIBLE]   |   |       |
|-------------------------|--------|-----------------|
| signed                  |   | signed          |
|                    |   |            |
| [ILLEGIBLE]             |   |       |
| print      name         |   | print      name |
|                    |   |            |
| Chair      & CEO    |   |       |
| title                   |   | title           |
|                    |   |            |
| Aug      27/2007        |   |       |
| date                    |   | date            |

| [ILLEGIBLE]          |   |       |
|----------------------|--------|-----------------|
| signed               |   | signed          |
|                 |   |            |
| [ILLEGIBLE]          |   |       |
| print      name      |   | print      name |
|                 |   |            |
| General      Manager |   |       |
| title                |   | title           |
|                 |   |            |
| 14/09/2007           |   |       |
| date                 |   | date            |

| /s/      F. Bach  |   |     |
|------------------------|--------|--------------------|
| signed                 |   | signed             |
|                   |   |               |
| F.      BACH           |   |     |
| print      name        |   | print      name    |
|                   |   |               |
| CEO                    |   |     |
| title                  |   | title              |
|                   |   |               |
| [ILLEGIBLE]            |   |     |
| date                   |   | date               |

----

| Country |   | Filing Date    |   | Serial No. |   | PubIn Date     |   | Publn No. |   | Issue Date |   | Patent No. |
|---------|--------|---------------------|--------|-----------------|--------|---------------------|--------|----------------|--------|-----------------|--------|-----------------|
| Europe1 |   | 18 Aug 93 |   | 93202428.4      |   | 09 Mar 94 |   | 586002         |   | Granted         |   | 586002          |

| Country |   | Filing Date2   |   | Serial No. |   | Publn Date     |   | Publn No. |   | Issue Date |   | Patent No. |
|---------|--------|---------------------|--------|-----------------|--------|---------------------|--------|----------------|--------|-----------------|--------|-----------------|
| Europe* |   | 15 Nov 95 |   | 95203126.8      |   | 22 May 96 |   | 712,863        |   | Granted         |   | 712,863         |

----

----

----

|   | 1. | A registration study in glioma.      It is provisionally estimated that enrolment will be in the range of 80 –      100 patients. |
|--------|----|-----------------------------------------------------------------------------------------------------------------------------------------|

|   | 2. | A pilot study in paediatric brain      tumours. It is provisionally estimated that enrolment will be in the range      of 6 – 10 patients. |
|--------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 3. | A registration study in      paediatric brain tumours. It is provisionally estimated that enrolment      will be in the range of 60 – 80patients. |
|--------|----|---------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 4. | A pilot study in metastatic      pancreatic cancer. It is provisionally estimated that enrolment will be in      the range of 14 – 20patients. |
|--------|----|------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 5. | Application for Orphan Drug      Status for the Product with theEMEA. |
|--------|----|-----------------------------------------------------------------------|

----

----